<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764829</url>
  </required_header>
  <id_info>
    <org_study_id>FHCRC - 1980.00</org_study_id>
    <secondary_id>R01HL091744</secondary_id>
    <secondary_id>IR-5957</secondary_id>
    <nct_id>NCT00764829</nct_id>
  </id_info>
  <brief_title>Blood Samples to Evaluate Biomarkers of Donor Chimerism</brief_title>
  <official_title>Blood Samples to Evaluate Biomarkers of Donor Chimerism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are interested in patient-specific factors that may affect the balance of recipient cells
      and donor cells in patients who receive stem cell transplants. We will look at the way the
      patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these
      two drugs affect the patient's body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Donor T-cell chimerism</measure>
    <time_frame>Day 28 post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure to fludarabine and mycophenolate mofetil and their breakdown products.</measure>
    <time_frame>Before and after transplant</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Leukemia</condition>
  <condition>Hodgkins Disease</condition>
  <condition>Non-hodgkins Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma,DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hematopoietic stem cell transplant patients receiving fludarabine and mycophenolate
        mofetil.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with a hematologic disease or malignancy

          -  Scheduled to receive nonablative conditioning with fludarabine and total body
             irradiation

          -  Donor is well-matched by high resolution DNA techniques.

          -  Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an oral
             calcineurin inhibitor.

          -  Age &gt;18 years at the time of enrollment.

        Exclusion criteria:

        -Diagnosed with an immunodeficiency disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeannine S McCune, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>February 13, 2012</last_update_submitted>
  <last_update_submitted_qc>February 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jeannine S. McCune, PharmD</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>fludarabine</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>mycophenolic acid</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

